A randomized, double-blind, parallel-controlled, phase I clinical study comparing the pharmacokinetic characteristics, safety, and immunogenicity of HWS111 injection and erenumab injection (trade name: Aimovig®) in healthy adult Chinese subjects (ChiCTR) - Oct 16, 2026 - P1 | N=128 | Completed | Sponsor: The Second Hospital of Anhui Medical University; The Second Hospital of Anhui Medical University
New P1 trial • CNS Disorders • Migraine
|